

SAA-ATLANTA IMPACT REPORT





OUR LOCAL BENEFICIARY



SUPPORTED SINCE 2013

SAA-ATLANTA HAS GRANTED OVER \$3.3 MILLION

> TO FIGHT CANCER SINCE 2013





LYMPHOBLASTIC LEUKEMIA

Children's



OSTEOSARCOMA

PEDIATRIC CANCER

BLOOD



NEUROBLASTOMA

GRANT RECIPIENTS



Dr. Waitman Aumann Focus: How a developmental protein, called SIX1, can lead to a worse prognosis in pediatric leukemias.



Dr. Dailia Benita Francis Focus: How immune molecule Siglec-15 is expressed at high levels on a specific type of lymphomas can develop new therapies.



Dr. Jenny Shim Focus: Understanding why neuroblastoma does not respond to different types of therapies and how we can identify novel treatments to improve patient outcomes.



Dr. Sherri Smart Focus: Applying biotechnology to improve outcomes for pediatric osteosarcoma patients.



Dr. Xu Ji Focus: Evaluate disparities in pediatric cancer outcomes by health insurance coverage and other disparities.

Swim Across America-Atlanta funding supports young investigators and their research projects at the Aflac Cancer Center. **Support for young investigators provides funding to a cohort of promising investigators and future research leaders to encourage and promote quality research in clinical oncology.** Swim Across America funding enables them to develop the preliminary data necessary to successfully compete for major research grants.

CHILDHOOD CANCER IN THE UNITED STATES BY THE NUMBERS

47 CHILDREN DIAGNOSED WITH CANCER EVERY DAY



1 IN 5 CHILDREN DO NOT SURVIVE

ONLY 11

DRUGS DEVELOPED AND APPROVED SPECIFICALLY FOR CHILDREN IN THE LAST 25 YEARS **ONLY 8%**

OF NIH FUNDING ALLOCATED TO CHILDHOOD CANCER RESEARCH

95%

OF SURVIVORS WILL EXPERIENCE A SIGNIFICANT SIDE EFFECT BY AGE 45